文献速递神经肿瘤

procaspase-3激活剂PAC-1联合羟基脲或替莫唑胺治疗高级别脑膜瘤:细胞培养与犬脑膜瘤患者评估

Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
PubMed 文献 · Neuro Oncol · 2021-01-01

高级别脑膜瘤缺乏FDA批准药物,本研究评估procaspase-3激活剂PAC-1在脑膜瘤细胞中诱导凋亡的能力,并探索其与羟基脲或替莫唑胺联合的效果。细胞培养中PAC-1+羟基脲具协同作用,PAC-1+替莫唑胺呈加和至协同效应;在少量犬脑膜瘤患者中,PAC-1+羟基脲稳定疾病但肿瘤内凋亡无变化,而PAC-1+替莫唑胺使全部三只犬肿瘤负荷降低。结果提示PAC-1+替莫唑胺可能是治疗人脑膜瘤的潜在有效组合。

要点

  • PAC-1联合替莫唑胺在犬脑膜瘤患者中降低肿瘤负荷
  • PAC-1联合羟基脲在犬中稳定疾病但未增加肿瘤凋亡
  • 宠物犬脑膜瘤模型可用于评估脑膜瘤治疗策略

核心结论

  • PAC-1联合替莫唑胺可能是治疗人脑膜瘤的潜在有效组合。
  • 纳入宠物犬作为评估脑膜瘤治疗策略的手段具有实用性。

研究设计与样本

  • 研究在脑膜瘤细胞培养中评估PAC-1诱导凋亡及与羟基脲或替莫唑胺联合的效果。
  • 两种联合方案进一步在少量犬脑膜瘤患者中通过MRI评估,并对接受PAC-1+羟基脲的患者评估新型凋亡示踪剂[18F]C-SNAT4。

主要发现

  • 在脑膜瘤细胞系培养中,PAC-1+羟基脲具协同作用,PAC-1+替莫唑胺呈加和至协同效应。
  • 在犬脑膜瘤患者中,PAC-1+羟基脲导致疾病稳定且肿瘤内凋亡无变化。
  • 在犬脑膜瘤患者中,PAC-1+替莫唑胺使全部三只接受治疗的犬肿瘤负荷降低。

临床怎么用

  • PAC-1联合替莫唑胺可作为人脑膜瘤的潜在治疗方向进一步研究。
  • 宠物犬脑膜瘤患者可用于临床前评估脑膜瘤治疗策略。

局限性

  • 犬脑膜瘤患者样本量小,仅少量犬接受治疗。
  • 缺乏预测性临床前模型是脑膜瘤药物开发的挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival. Currently, there are no FDA-approved drugs for meningioma, highlighting the need for new therapeutic options, but development is challenging due to the lack of predictive preclinical models. METHODS: To leverage the known overexpression of procaspase-3 in meningioma, PAC-1, a blood-brain barrier penetrant procaspase-3 activator, was evaluated for its ability to induce apoptosis in meningioma cells. To enhance the effects of PAC-1, combinations with either hydroxyurea or temozolomide were explored in cell culture. Both combinations were further investigated in small groups of canine meningioma patients and assessed by MRI, and the novel apoptosis tracer, [18F]C-SNAT4, was evaluated in patients treated with PAC-1 + HU. RESULTS: In meningioma cell lines in culture, PAC-1 + HU are synergistic while PAC-1 + TMZ show additive-to-synergistic effects. In canine meningioma patients, PAC-1 + HU led to stabilization of disease and no change in apoptosis within the tumor, whereas PAC-1 + TMZ reduced tumor burden in all three canine patients treated. CONCLUSIONS: Our results suggest PAC-1 + TMZ as a potentially efficacious combination for the treatment of human meningioma, and also demonstrate the utility of including pet dogs with meningioma as a means to assess anticancer strategies for this common brain tumor.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Tonogai EJ, Huang S, Botham RC, et al. Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. Neuro Oncol. 2021. PMID: 34216463. doi:10.1093/neuonc/noab161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。